Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Webcast: Navigating new frontiers: Ways to find space in the future RA market

April 9, 2019 | Pharma, Webcast, healthcare, rheumatoid arthritis 

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Video: Strategic engagement case study

Supporting the launch of a global vaccine with a programme of market research and strategic insights

Webcast: The virtual patient: How to use AI-powered conjoint to understand complex treatment decisions

Watch to find out how a combination of virtual patients and artificial intelligence can help you to better understand physicians’ decision making processes.

Research Partnership appoints new CEO

Research Partnership has appointed Gareth Phillips to take over as CEO

Infographic: Therapy Watch Hyperlipidaemia

Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study.

Article: The rise of the healthcare influencer

In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space.

Personalized Oncology: Calling for a New Kind of Partnership:

In the 1990s, biomarkers were the future of personalized medicine and a “lab on a chip” was the holy grail of understanding patient health. As much as past predictions of...

How to elevate your communications testing with AI powered insights and analytics

Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

EVOKE STRENGTHENS LEADERSHIP TEAM IN EUROPE TO DELIVER MORE INTEGRATED CLIENT SOLUTIONS

*Corrina Safeio, promoted to Group Managing Director taking on responsibility for Evoke London and Evoke Mind+Matter *Lee Wales, promoted to Deputy Managing Director at Evoke Mind+Matter UK *Holly Ford, promoted...

Infographic: Therapy Watch Psoriasis

Our PsO infographic offers an introduction to the real-world patient insights collected by our Therapy Watch PsO study.

Article: How behavioural economics can help you build better brand communications

For pharma marketers, accelerating brand performance means maximizing return on investment. Your campaigns need to trigger the right emotions, and the right actions, in your audience.